CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.
CNMD - CONMED Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$37.50
DETAILS
HIGH:
$39.00
LOW:
$36.00
MEDIAN:
$37.50
CONSENSUS:
$37.50
DOWNSIDE:
13.81%
Stock News
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
CONMED Corporation (NYSE: CNMD) today announced that its [url="]AirSeal Robotic Solution[/url] is now indicated for use with Intuitive's 8 mm hex cannulas us
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive's 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive's portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I.
Bessemer Group Inc. Purchases 36,940 Shares of CONMED Corporation $CNMD
Bessemer Group Inc. boosted its position in CONMED Corporation (NYSE: CNMD) by 46.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 116,429 shares of the company's stock after purchasing an additional 36,940 shares during the period. Bessemer Group Inc. owned about 0.39% of CONMED worth
Allspring Global Investments Holdings LLC Increases Holdings in CONMED Corporation $CNMD
Allspring Global Investments Holdings LLC grew its position in shares of CONMED Corporation (NYSE: CNMD) by 39.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 582,733 shares of the company's stock after buying an additional 166,301 shares during the quarter.
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdomi.
CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro.
CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. “We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED,” said Patrick J. Beyer, CONMED's President and Chief Executive Officer. “John brings deep healthcare and.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.
Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (âBoardâ), effective July 1, 20
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total.
Is the Options Market Predicting a Spike in CONMED Stock?
Investors need to pay close attention to CNMD stock based on the movements in the options market lately.
CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up
CNMD tops Q1 estimates despite sales dip, lifts 2026 organic growth outlook as strategic shift sharpens focus on higher-growth segments.
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript
Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) Q1 Earnings and Revenues Beat Estimates
Conmed (CNMD) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.95 per share a year ago.
CONMED Corporation Announces First Quarter 2026 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decreased 1.3% year-over-year as reported and 2.9% in constant currency. Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products. Domestic revenue decreased 5.8% year-over-year. Domestic sales growth was impacted by a $15.2 million decrease in sales from th.
A Look at Conmed Corp (CNMD) After 3.3% Gain -- GF Value $78.09 vs Price $39.73
On April 14, 2026, Conmed Corp (CNMD) shares rose 3.3% to a current price of $39.73. The stock is trading within a 52-week range of $33.21 to $61.08, reflecting
Price Targets
Wells finds Conmed sale report 'little surprising' after refinance
$39.00
(was $41.98)
Wells Fargo
Conmed initiated with a Market Perform at BMO Capital
$36.00
(was $33.59)
BMO Capital
Conmed price target lowered to $61 from $91 at Needham
$61.00
(was $57.19)
Mike Matson
·
Needham
Needham Reiterates Buy Rating on CONMED (CNMD)
$97.00
(was $66.59)
Mike Matson
·
Needham
CONMED (CNMD) PT Lowered to $95 at Piper Sandler
$95.00
(was $64.34)
Matt O\'Brien
·
Piper Sandler
CONMED (CNMD) PT Lowered to $107 at Needham
$107.00
(was $70.01)
Mike Matson
·
Needham
Conmed price target lowered to $108 from $118 at Piper Sandler
$108.00
(was $83.39)
Matt O'Brien
·
Piper Sandler